Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirectâ„¢ Ketamine Topical Cream in Treating PTSD
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer
MIAMI, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (“Psycheceutical” or the “Company”) (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, announced the Company’s Chief Visionary Officer, Zappy Zapolin, has been added to The Benzinga Psychedelics Advisory Council.
MIAMI, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (“Psycheceutical” or the “Company”) (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatment, announced that it has entered into an exclusive option that provides Psycheceutical an opportunity to acquire a majority equity stake in Vici Health Sciences (“Vici”). The total exercise price under the option would be approximately $10.5 million, which would be paid part in cash and part in equity. The Company has until April 2023, unless extended by the parties, to exercise the option. Vici is an end-to-end pharmaceutical research and development company specializing in taking projects from pre-clinical research through the Phase 2 stage of FDA approval.